Histologic Alterations Produced by Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) in SENCAR Mouse Skin: Relationship to Skin Tumor Promoting Activity  by Kruszewski, Francis H. et al.
Histologic Alterations Produced by Chrysarobin 
(1,8-dihydroxy-3-methyl-9-anthrone) in SENCAR 
Mouse Skin: Relationship to Skin Tumor 
Promoting Activity 
Francis H. Kruszewski. Ph.D.: Masashi Naito. M .D .• Yukiko Naito. M.D .• and John DiGiovanni. Ph.D. 
University o(Texas System Cancer Center. Science Park-Research Division, Smithville, Texas 
Histologic changes induced in SEN CAR skin following a 
single treatment with chrysarobin (1.8-dihydroxy-3-
methyl-9-anthrone) exhibited differences in time course 
from that observed with 12-0-tetradecanoylphorbol-13-ac-
etate (TPA). Although not sigllificantly different. maximum 
elevations in epidermal thickness. total number of nucleated 
epidermal cells. and dark basal keratinocytes (DCs) induced 
by 220 nmol chrysarobin occurred at 96 h after treatment. 
while those induced by 3.4 nmol TPAoccurted at 48 h. Both 
compounds elicited comparable inflammatory responses. 
Twice-weekly applications of chrysarobin for 2.5 weeks 
induced a moderate hyperplasia. increase in total nucleated 
epidermal cells. and increased DCs at 48 and 96 h afrer the 
last treatment, with a higher value for these parameters DC· 
curring at 48 h. [nterestingly. the magnitude of these 
changes was similar to that observed after a single applica-
A nthrone derivatives [e.g., anthralin (1,8-dihydroxy-9-anthrone) and chrysarobin (1.8-dihydroxy-3-methyl-9-anrhrone)] have been used in the treatment of psori-asis for many years (reviewed in Ref 1). Earlier studies have shown that anti-psoriatic anthroncs arc not carci-
nogenic when applied topically to mouse skin [2,3]; however, they 
are effective skin irritants [4,5). In addition, anthrone derivatives 
such as anthralin and chrysarobin have been shown to be effective 
skin tumor promoters in mice previously initiated with subcarcino-
genic doses of, for example, 7, 12-dimethylbenz(a)anthracene 
(DMBA) [2.3.6J. More recently. studies in our I.boratory have 
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Abbreviations: 
8M: basement membrane 
CHR: chrysarobin 
DC: dark basal ke~tinocyte 
DMBA: 7. 12-dimethylbenz(a)al1thracene 
EPP: ethylphenyl propriolate 
DOC: ornithine decarboxylase 
PMN: polymorphonuclear leukocyte 
TPA: 12-0-tetradecanoylphorbol-13-aceute 
cion. In contrast, twice-weekly applications ofTPA induced a 
dramatic, potentiated induction of epidermal hyperplasia and 
DCs. Once-weekly applications of chrysarobin led to a po-
tentiated induction of both hyperplasia and DCs compared to 
the twice-weekly treatment regimen and also more effec-
tively promoted epidermal papillomas in previously initiated 
SEN CAR mice. Skin sections from mice treated with chry-
sarobin displayed overt signs of epidermal toxiciry including 
altered basal cell morphology and a decreased number of basal 
cells per 125 flm of basement membrane. Hypetplasia in-
duced by multiple but not single treatmenrs wirh chrysarobin 
and TPA correlated quantitatively with their papilloma pro-
moting activity. In addition, the data suggest that epidermal 
toxicity may playa role in tumor promotion by anthrones. ] 
blllesl Dermatol 92:64 - 71, 1989 
shown that both chrysarobin and anthralin are very efficient skin 
tumor promoters in mice because they produce carcinoma responses 
similar co those produced by the potent skin tumor promoter 12-0-
tetradecanoylphorbol-13-acet;).te (TPA) {7.8J. It is of interest. 
therefore, to fully characterize the cellular, biochemical. and molec-
ular effects produced by this class of compounds in relation to their 
skin rumor promoting activity and to compare these with the potent 
tumor promoting pharbol esters. 
The phenomenon of tumor promotion in general has been exten-
sively studied using phorbol esters such os TPA [9.IOJ. While the 
mechanism of tumor promotion is yet unknown, specific cellular 
and biochemical responses have been associated with the mecha-
nism of action ofTPA in mouse skin. Those events which correlate 
best with the skin-tumor promoting action ofTPA (reviewed in 
Refs II and 12) ore the induction of eRidennal hyperplasia [13J. 
dark basal keratinocytes (DCs) [13-151. a dermal infl.mmatory 
response [16J, .nd epiderm. I ornithine decarboxylase (ODC. EC 
4.1.1.17) activity followed by increased polyamine levels [17.18J . 
Furthermore, the promotion response to TPA is presumably me-
diated in part by its ilHeraction with protein kinase C (PKC). the 
putotive TPA receptor [19 - 22J. 
In general, there is only limited information on the histologic 
alterations induced by other classes of tumor promoters in mouse 
skin. A previous limited study from our laboratory reported on the 
epidermal hyperplasia and skin edema associated with a single topi-
cal application of both anthCdlin and chrysarobin in SENCAR mice 
[7J. These dota suggested that the hyperplosi. induced by anthralin 
and chrysarobin shared differences in both magnitude and time 
course when compared to the TPA response. Klein-Szanto and 
SI;).ga [15] demonstrated that anthralin was a moderate inducer of 
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dark basal keratinocytes compared to TPA in SENCAR mice. M:w-
nino C't al123J have shown that NMRI mice developed a visible skin 
irritation in response (0 a limited number of treatments (three appli-
ca tions per week for 2 weeks) with anthralin or lO-propionyl 
anthralin . They also observed that these compounds elicited epider-
mal hyperp lasia after a chronic treatment regimen (three applica-
tions per week for 50 weeks). In a comparable study using SEN CAR 
mice, Vilukscla et al [24J reported that visible skin irritation and 
histologically observed inflammatory changes were evident after 
chronic treltlllcnc regimens (three applications per week for up CO 
36 weeks) using anth ra lin or several 10-acyl analogues. 
The present study was designed to provide an in-depth analys is of 
the histologic changes produced in the skin ofS_ENCAR mice fol-
lowing horh single and Illultiple applications of chrysarobin in com-
parison with TPA . As part of the experimental design. two multiple 
applica tion protocols were used with chryslrobin consisting of a 
series of five treatments given at different application frequencies; 
rwice-weekly for 2.5 weeks or once-weekly for 5 weeks. W e have 
recentl y del1lonsrrated that the once-weekly application protocol is 
more efficient for the induction of epidermal ODC [25] and papil-
loma formation 181 in SEN CAR mice. The present data indicate that 
promoting doses of chrysarobin effectively induced epidermal hy-
perplasia, Des. and dermal inflammatory changes. In addition, 
these responses, which are known to be important components of 
skin tumor promotion by phorbol esters, va ried as a function of 
trea tment protocol in direct relation to skin tumor promoting activ-
iry. Finall y, evidence is presented to suggest that epidermal toxiciry 
may be an important component of the promolion response to 
anthrone tllmor promoters. 
MATERIALS AND METHODS 
Chemicals DM13A was obtained from the Eastman Kodak Co. 
(Rochester, NY). TPA was purchased from Chemicals for Cancer 
Research, Inc. (Eden Prairie, MN). Chrysarobin was purchased 
from le N Phannaceuticals, Inc. (K and K Laboratories Division. 
Plainview, NY). and was purified by column chromatography as 
described in a previous study 16}. All other chemicals and reagents 
used were of the highest purity deemed necessary. 
Animals and T reatments Female SENCAR mice were obtained 
from the National Cancer Institute (Frederick, MO). At 7 weeks of 
age, the backs of the mice were carefull y shaved using surgical 
clippers. Mice we're allowed to stabilize for 2 days, and only those 
mice in the resting phase of the hair growth cycle were utilized. All 
chemicals were applied topically to the shaved area. Animals re-
ceived ei ther a single or a Illultiple treatment regimen. The twO 
multiple treatment regi mens, consisting of five tre':l(menrs. were 
given either twice-weekl y for 2.5 weeks or ollce-weekly for 5 
weeks. For the single application and twice-weekly protocols. 
groups of three mice each were treated with 0.2 ml acetone solu-
tions containing 3.4 1111101 TPA or 220 nmol chrysarobin. For the 
once-weekly protocol. groups of two mice each were treated with 
220 nmol chrysarobin in 0.2 ml acetone. All compounds were dis-
solved in acetone immedi:aciy prior to usc. Comrol groups were 
treated either once or five timcs with 0.2 ml acetone for the single 
and multiple treatment protocols. respectively. Mice were then 
killed at va riolls times afte r the last application of each promoter. 
Histolog ic Prepar atio n Skin from treated animals was excised, 
fix ed with 3% gluta raldehyde in 0.05 M Sym-coJlidine buffer (pH 
7.4). post-fixed with 2% osmium tetroxide in 0.1 M cacodylate 
buffer (pH 7.4), and embedded in Po ly/Bed 812 [14J. Several 
blocks were embedded for each animal, and two blocks were se-
lected on the criterion of the best possible o rientation. From these 
blocks. I-pm-thick sections were prepared and stained with 0.05% 
toluidine blue. 
Morphometric Studies and Quantitative Eva luations The 
measurements of the epidermal thickness (except the horny layer) , 
the dermal thickness (from the basement membrane to s.c adipose 
tissue) , the number of basal and total epidermal nuclea ted cel ls per 
125 pill lengrh of basement membrane (BM), and the number of 
HISTOLOGIC EFFECTS OF CHRYSAnO DIN 6S 
PMNs and mast cel ls per 250 JIm length of BM were performed 
lIsing an Olympus ocular micrometer at objective lens magnifica-
tion of 40x. PMNs and Illast ce lls were coull ted in all areas of the 
dermis from the BM to the upper surface of the ad ipose cel ls along a 
250 Jim horizontal length. At least 12 areas of a section from each 
block were measured at random for each parameter. We defined the 
DCs as cel ls hav ing darkly stained nuclei and cytoplasm using tolui-
dine bl ue and without degenerative changes such as large intracyto-
plasmic vacuoles or wide imercellular spaces. The quantitative his-
tology data preseneed represents mean ±S.E.M., and these fi gures 
were calculated from at least four sections of sk in (two mice per 
group) and in some cases six sections or more (three mice per group). 
Sections sampled from an individual mouse were taken from differ-
ent areas of dorsal skin. Statistical significance of the differences 
I)(." twcen means was evaluated with Student 's t-test. The level of 
signi ficance was set at ps.05. 
T umor Induct ion Experiments Each experimental group con-
tained 30 preshaved mice. Mice were initiated with 25 nmol of 
DMBA and beginning ["\\10 weeks after initiation, received topicaJ 
applications of chrysarobin given either once or twice weekly. A 
th ird experimental group received twice-weekl y applications of 3.4 
nmol TPA. The incidence of papillomas was observed and recorded 
week ly. Papi llomas were removed at random for histologic verifica-
tion. Sratistical analyses of the difference berween mean papilloma 
responses (i.e .. papillomas per mouse) were performed using stu-
dents t-tesr. 
RESULTS 
E ffects of a Single T opical Applica tio n For the present study 
we chose a dose of220 11mol chrysarobin. W e have recentl y shown 
that til is dose is a maxinl:tl skin tUlllor promQ[ing dose in female 
SEN CAR mice [8J. Figure 1 shows the tillle course for the induction 
of epidermal hyperplasia (expressed as epidermal thickness) after a 
single topical application of220 nlllol chrysarobin . The data show 
thlt chrysarobin is a very effective hype rp13siogenic agent. lnterest-
in gly, the time course for induction of epidermal hyperplasia after a 
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Figure 1. Time course for the induction of epidermal hyperplasia after a 
511lg1c Jpplic3tlon of chrysarobin (220 nmol per mouse) or acetone (0.2 ml). 
Also shown for comparative purposes is the epidermal hyperplasia 48 and 
96 h after a single application ofTPA(3.4 nmol). Three mice were used for 
each ("xperiment;1! group. Values were calculated from:H least two sections 
from each animal and represent mean ±S.E.M. 
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single topical application of chrysarobin was diff"crenc from that 
observed with TPA. Previous work has shown that the hyperplasia 
produced in mouse skin by a single topical application of TPA 
reaches a peak by 48 h [12,26J. In comrasr, the hyperplasia produced 
by a single application of chrysarobin reached a peak by 96 h after 
treatment. In addition, significant epidermal hy~rplasia was evi-
dem even 14 d after a single topical application of the anthrone. For 
comparison, the changes in epidermal thickness after a single topical 
application of 3.4 nmol TPA are given for both 48 and 96 h after 
treatment. It should be evident that the epidermal hyperplasia had 
begun to subside by 96 h after treatment with TPA. It is also inter-
esting to nOte that the magnitude of the peak increases in epidermal 
thickness for chrysarobin and TPA were not significantly different 
afte r a single treatment. 
Table 1 more clearly demonstrates this latter point, especially 
when comraring rhe total number of nucleated epidermal cells per 
125 Jim 0 BM and also presents a more detailed analysis of the 
epidermal and dermal changes observed at 48 and 96 h after a single 
app lication of chrysarobin or TPA. In addjtion, Fig 2 shows the 
histologic appearance of skins treated with a single application of 
chrysarobin or TPA. Argyris r261 demonstrated that the suprabasal 
cells increased significantly after a single treatment with 17 nmol 
TPA to the skins of CD-1 mice, whereas the basal cells actually 
decreased in number within 1-2 d after treatment. We noted a con-
sistent and reproducible decrease in the number of nucleated basal 
cells 48 h after treatment with chrysarobin (Table I) but not with 
TPA at the dose utilized. In addition, the epidermal basal cells from 
mice treated with chrysarobin had an unusual morphology, being 
relatively large and exhibiting both swollen nuclei and cytoplasm 
(Fig 2, pa"el C). At 96 h after treatment, the number and morphol-
ogy of epidermal basal cells from mice treated with chrysarobin 
were comparable to those of the acetone control group (Fig 2, panels 
B alld D). TPA (3.4 nlllol per mouse) induced only a marginal 
increase in the number of epidermal basal cells at both 48 and 96 h 
after treatment, and these cells possessed a "normal-looking" mor-
phology when compared to sections from acetone comrol mice. 
Chrysarobin was an effective inducer of epidennal DCs with a 
greater number present at 96 h compared to 48 h after a single 
topical application (Table I) . We have previously demonstrated that 
there is an excellent linear correlation between the magnitude of 
epidermal hyperplasia produced by a wide variety of chemical pro-
moters and the log percentage of DCs induced by the same agents 
[27J. The data presented in Table I are consistent with these obser-
vations in that the percentage of dark cells was greatest when the 
hyperplasia was maximal. Although we did not examine the induc-
tion of DCs at time points other than 48 and 96 h after treatment we 
assume, based on our previous work, that the value obtained for 
chrysarobin at 96 h would be at or very ncar the maximal response. 
It should also be pointed out that the maximal response observed for 
TPA at 48 h (16.4 ± 7%), although higher, was nor significantly 
(p> .05) different than that observed for chrysarobin at either 48 or 
96 h. 
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Significant dermal thickening was induced 48 h after treatment 
with either chrysarobin orTPA; however, at 96 h the values in both 
treatment groups were comparable to the acetone comrol. TPA and 
chrysarobin induced a significam inflltration of inflammatory ceils, 
specifically PMNs, into the dermis at 48 and 96 h after a single 
treatment. Dermal mast cell numbers were not significantly altered 
or only slightly altered at 48 and 96 h after treatment with chrysar-
obin or TPA. While the maximallevds of dennal thickening and 
PMN infiltration induced by chrysarobin and TPA were signifi-
cantly different than acetone concrol values (p< .05), they were not 
significantly different frolll each other. Also. the time course for the 
development of these dermal changes following treatment with 
chrysarobin and TPA were similar (Le., peak induction at 48 h after 
treatlllent). 
Effects of Multiple Treatments Skin tumor promotion proto-
cols involve multiple treatment regimens, and in the case of the 
phorbol esters the optimum treatment is rwice weekly. In order to 
fully understand those histologic changes essential for skin tumor 
promotion by other classes of promoters it is necessary to examine 
changes occurring after more than one treatment. Tables 11 and III 
and Fig 3 summarize the histologic changes in the skins of SEN-
CAR mice after five applications of chrysarobin (220 nmol) given 
either twice weekly (Table II) or once weekly (Table III). Included 
for comparison are the histologic changes in the skins of mice 
treated with five applications ofTPA (3.4 nmol) given twice weekly 
(Table II). The most striking observation when comparing rwice-
weekly applications of chrysarobin and TPA is the lack of poten-
tiaced hyperplasia with the former compound. In this regard, five 
applications of TPA, given twice-weekly, induced a significantly 
greater epidermal hyperplasia in terms of epidermal thickness and 
DC induction compared to a single application of this promoter 
(Tables I and II , Fig 2E,F and 3G,H). In contrast, five applic.:l.tiolls 
of chrysarobin given twice weekly did not induce a signiflcamly 
greater epidermal hyperplasia than observed after a single applica-
tion (Tables I and II, Fig 2C,D and 3E,F). The time course for the 
epidermal changes produced by twice-weekly applications of chry-
sarobin was shifted earlier compared to a single application and the 
kinetics were more like that with TPA, where maximal values were 
obtained 48 h after the last treatment (Table II). 
The total number of nucleated cells increased slightly, but the 
basal cells were again significantly decreased in number 48 h after 
the last treatment with chrysarobin in this twice-weekly application 
protocol (Table II). Furthermore, the epidermal basal cells observed 
in sections 48 h after the last application of chrysarobin again had an 
unusual morphology, being relatively large and exhibiting both 
swollen nuclei and cytoplasm (Fig 3, parrel E). Thus, similar alter-
ations in basal cell number and morphology were observed follow-
ing both single (Table I, Fig 2) and rwice-weekly treatments (Table 
II, Fig 3) of chrysarobin. 
As noted in the Introduction, we have recently demonstrated that 
chrysarobin is a more effective promoter of papilloma formation 
Table I. Changes in the Skin of SEN CAR Mice after a Single Application with Various Promotersa 
No. of Nucleated No, of Dermal 
Epidermal Cells 
% 
Inflammatory Cells 
Thickness of (,1m) per 125 ,mn of DM pc" 250 ~m of 8M 
Time After Dark Basal 
Treatment Promoter Epidermis Dermis Basal uyer Taral Keratinocytes PMN Mast 
Cells 
Acetone 15.8 ± 1.0 153.8 ± 13.0 17.6 ±0.6 24.7 ± 0.9 0.8 ± 0.2 0.05 ± 0.1 4.5 ± 0.7 
48 h Chrysarobm 20.8 ± 1.2 194.0 ± 23.5 13.0 ± 0.3 24.S ± 1.4 8.2 ± 2.4 19.6 ± 5.2 5.1 ±0.9 
TPA 42.8 ± 2.1 223.0 ± 45.0 19.7 ± 1.4 40.4 ± 0.6 16.4 ± 7.0 24.0 ± 7.2 7.6 ± 0.9 
Acemne 16.0 ± 1.0 148.5 ± 17.0 17.7 ± 0.4 25.0 ± 0.8 1.0 ± 0.4 0.08 ± 0.2 4.9 ±0.8 
96 h Chrysarobin 42.5 ± 1.8 163.5 ± 13.5 18.4 ± 0.8 40.7 ± 1.6 8.2 ± 1.5 3.9 ± 1.7 4.0 ± 0.6 
TPA 35.8 ± 1.2 168.8 ± 12.5 19.6 ± 0.9 39.0 ± 0.9 10.0±3.9 5.9 ± 1.9 5.0 ± 1.3 
• Three mlcc were used for uch lre:Hnlent. TPA (3.4 nmol) and chrysuobln (220 nmol) in 0.2 ml acetone or the same volume of acetone were applied once on the backs of mice. 
Figures were calculated from twO sections from each ammal :lInd repre~nt mean ±S.E.M. 
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Figure 2. Respo nse of the skill 01 ~tNCAR mice 48 and 96 h after a single application of 0.2 011 acetone, 220 nmol chrysarobin, or 3.4 nmol TPA. Panels A 
and B: 48 and 96 h, respectively , after treatment with 0.2 011 acetone. PIli/tis Cand D: 48 and 96 h, respectively, after treatment with 220 nrnol chrysarobin. 
The epidermis showed slight hyperplasia and altered ccllmorphology 48 h after treatment. In addition, the number of basal cells were reduced. At 96 h after 
treatment, the epidermis showed a good hyperplaSia. PtJnt/s E and F: 48 2nd 96 h after treatment with 3.4 mnol TPA. The epidermis showed a good 
hyperplasia 48 h after treatment. At 96 h after treatment, the epidermis still showed a good hyperplasia bur the magnitude was less than that observed in 
chrysarobin treated skin. Epon~toludine blue: x420; Bar 50 JlIll. 
when given once-weekly compared to twice-weekly (8). Table IV 
summarizes the results of a tumor experimenr conducted concur-
renely with our histology studies comparing the papilloma response 
in mice receiving OnCc- or twice-weekly applications of chrysaro-
bin. A once-weekly application frequency with 220 nmol chrys:uo-
bin produced approximately twice rhe number of papillomas com-
pared with the twice-weekly application frequency (p< 0.5). The 
data ill Table III and Fig 3, pallels C and D demonstrate that a 
once-weekly application of chrysarobin. unlike the twice-weekly 
trea tment , produced a potentiated hyperplasia compared to that 
observed after a single application of the promoter. In addition. rhe 
time course for hyperplasia induction after the last of five twice-
weekly applications of chrysarobin was again identical to that 
observed with ollce-weekly applications of TPA. The maximum 
percentage of Des induced was significantly greater in the once-
weekly compared to the twice-weekly application protocol 
(p<O.S). At the tilllC' points examined, the number of nucleated 
cells in rhe basal layer of mice treated once weekly with chrysarobin 
was comparable to the values found in the acetone control group. 
This observation was different than that for the chrysarobin groups 
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Table U. Changes in the Skin of SEN CAR Mice afcer Multiple Applications of Various Promoters Given Twice Weeklya 
No. of Dermal 
Time After 
No. of Nucleated Epidennal 
% 
InAammatory Cells 
Last 
Thickness of (pm) Cells per 125 Jim of 13M 
Dark Basal 
per 250 JJm of 8M 
Treatment Promoter Epidermis Dermis Bani Layrr Tora) Keratinocytrs PMN Mast Cells 
Acetone 15.2 ± 0.5 140.5 ± 3.2 17.4±0.2 24.7 ± 0.6 1.2±0.1 0 6.5 ± 0.3 
48 h Chrysarobin 41.3 ± 2.3 224.5 ± 2.5 13.0 ± 0.3 28.5 ± 0.8 8.4 ± 1.3 5.9 ± 1.6 8.0 ± 0.4 
TPA 71.5±4.9 229.0 ± 12.2 18.4 ± 0.3 39.8 ± 1.0 44.2 ± 3.9 11.4±1.8 11.6 ± 1.3 
Acetone 15.0 ± 0.5 134.2 ± 12.5 17.2±0.2 24.3 ± 0.5 1.0 ± 0.2 0 5.9 ± 0.3 
96 h Chrysarobin 36.5 ± 3.5 190.5 ± 4.2 18.9 ± 0.4 28.8 ± 1.2 5.2 ± 0.8 0.4 ± 0.1 7.2±0.6 
TPA 66.3 ± 4.3 208.5 ± 8.0 19.0±0.1 41.4 ± 0.3 31.9±3.9 8.0 ± 0.8 16.4±1.1 
• Three nl1cr wt"re used for e;ach experiment. TPA (3.4 nmol) ;and chryurobm (220 nmol) ill 0.2 ml :lccrone or thcs:ullc volulIleof :lceione were :l.pplled nve times on the b.acksof 
1I11Ce over ;a 2.5 wct"k period. willg :I. Iwicc-w«kly :lpplic:luon frequency. Figures were calculated from two seCtloru from each animal alld rt"prr-SCllt me:l.n ±S.E.M. 
treated singly or cwice weekly I where at 48 h after the last treatmenc 
there existed a significandy decreased number of nucleated basal 
cells. 
Thus, rhe above data demonstrace a good correlation between the 
magnitude of the induced hyperplasia, DC response. and efficiency 
for papilloma formation when comparing the once- vs, twice-
weekly applications of chrysarobin. Furthermore, neither multiple 
treacmem protocols with chrysarobin produced hyperplasia or in-
duced dark cells to the same exrenc as twice-weekly applications of 
TPA. In addition, TPA was much more effeccive at promoting the 
development of papillomas in SEN CAR mice. When taken co-
gether these data support an important role for epidermal hyperpla-
sia and dark cell induccion in skin rumor promotion by anthrones. 
DISCUSSION 
The anthrone class of tumor promocers has been hypothesized to 
work chrough an inirial mechanism distincc from the phorbol escers 
(reviewed in Ref28). This concept is based on various data, includ-
ing. differential papilloma formarion in DMDA-iniciaced mice [8], 
differential induction of epidermal ODC [25]. and the inability of 
anchrone promoters to interact direcrly wich the phorhol ester re-
cepeor [t 9,28}. The induction of epidermal ODe after a single 
crea[Tnent by chrysarobin is significanrly different, both in the mag-
nitude (lower) and time course (delayed) compared with TPA 
[2. t 6J. Our present observarions, which also support the above hy-
pothesis, indicare that the epidermal hyperplasia and DCs induced 
in SEN CAR skin following a single treatment with chrysarobin 
also exhibited a time course different from that observed wich TPA 
[12,26). Whereas significant e1evarions of epidermal thickness. 
rotal number of nucleated epidermal cells, and Des induced by 220 
nl110l chrysarobin were maximal at 96 h afcer a single creacmenc, 
rhose induced by 3.4 nmol TPA were maximal at 48 h. Interest-
ingly. the maximum values for rhe epidermal changes after a single 
Jpplication of chrysarobin or TPA were found to be very similar. 
Ic has been suggested cilJt the inducrion of epidermal hyperplasia 
is not sufficient for epidermal tumorigenesis in mouse skin (for 
review I see Refs 29 and 30) because of daca on a number of agems 
including acetic acid, cancharidin, Illezerein. and ethylphenyl pro-
priolare (EPP). These agents induce an epidermal hyperplasia simi-
lar to that produced by TPA after a single applicacion, but unlike 
TPA rhey are poor promoters of epidermal tumorigenesis in mice. 
However, Argyris has demonstrated that both acetic acid [31] and 
me2erein 132] are less effective hyperplastic agenrs because they 
cannot maintain the hyperplasia they initially produce when ap-
plied using multiple treatment regimens. The results of our presenc 
scudy, involving chrysarobin and TPA. support the concept that the 
magnicude of the suscained hyperplasia after multiple treatments 
correlates very well with the papilloma promoting ability of a given 
chemical. In this regard, results wirh the twice-weekly application 
protocol indicated chac TPA induced a sustained hyperplasia which 
was greater chan thac produced by chrysarobin in terms of epidermal 
thickness and tocal nucleated epidermal cells per 125,um 8M. In 
addition, che magnitude of the hyperplasia induced by twice-
weekly applicarions of chrysarobin was not significantly different 
rhan after a single applicacion. Results obtained using che once-
weekly application protocol with chrysarobin indicaced chat this 
prococol, which is opcimal for skin tumor promotion by anthrone 
promoters (Ref 8 and Table IV), is also mor(' optimal for induction 
of a sustained hyperplasia, It was also interesting to find that both 
rhe once-weekly and twice-weekly applicarion protocols with 
chrysarobin yielded a time course for che induction of hyperplasia 
which was closer to thac produced by TPA given twice weekly (i.e., 
maximum hyperplasia at 48 h). 
Argyris 133J has operationally defined a regenerative hyperplasia 
as an epidermal hyperplasia which is associated with tissue damage. 
The histologic signs of cissue damage include cell deach, karyor-
rhexis, pyknosis, cytoplasmic swelling, and an inflammatory re-
sponse. Although we did not measure epidermal toxicity directly, 
the results of Ollr present study suggest that the induction of epider-
mal hyperplasia by anthrones may result from chemically-induced 
tOxicity and a subsequent regenerative response. The da ta from our 
present study thac support the above hypochesis include 1) the de-
Table [D. Changes in the Skin of SEN CAR Mice after Mulriple Applications of Chrysarobin Given Once Weeklya 
No. of Drrma) 
Time After 
No. of Nucleated Epidermal 
% 
InAammatory Cells 
Thickness of (JJm) Cells per 125 JJm of BM per 250 Jlm of BM 
Last Dark Basal 
Treaunellt Promoter Epidermis Dermis B~) Layer Total Ker:uinocyccs PMN Mast Cells 
48 h Acetone 15.0 ± 1.0 147.5 ± 15.5 16.6 ± 0.4 24.5 ± 0.7 0.6±0.1 0 5.0 ± 0.5 
Chrysarobin 54.2 ± 3.2 235.5 ± 4.5 18.7±0.8 45.9 ± 2.8 14.2 ± 3.0 8.5 ± 2.9 7.4 ± 0.5 
96 h Acetone 17.8 ± 0.5 136.5 ± 3.5 18.2 ± 1.1 28.7 ± 2.9 1.9 ± 0.2 0 4.5 ± 0.6 
Chrysarobin 49.5 ± 1.5 225.0 ± 11.8 18.2 ± 0.5 46.0 ± 1.4 10.8 ± 2.2 2.2 ± 1.4 7.2 ± 0.4 
168 h Acetone 16.0 ± 0.8 159.5 ± 7.8 17.7 ±0.1 25.1 ±0.3 1.2 ± 0.3 0 5.8 ± 0.2 
Chrys:l.robm 31.0±0.1 198.5 ± 4.0 18.6 ± 0.3 39.6 ± 1.0 8.3 ± 0.0 0 6.8 ± 0.8 
• Two Illice weft" used for each expcnment. Chryurobm (220 nmol) In 0.2 Illl acclont': or the umt volumr- of :l.cetOllr- were :l.pphed nve IImeli on Ihe b:l.cksof mice ovcra 5-week 
pcnod.. usmg:l. once-weekly :l.ppliC:l.uon frequency. Figures werr- c:l.lcu!a.reo rrorn fWO ~ctlons from cach amm:l.l :l.lld (eprt'SC"nt mr-:l.1I ±S.E.M, 
Figure 3. Response of the skin of SEN CAR mice48 and 96 h afu:r multiple treatments with 0.2 ml act:tone, 220 nmol chrysarobin, or 3.4 nmol TPA. Pantls 
A :md B: 48 and 96 h, respectively. after rhe: last of five trearmeIHs with :IIcetonc: given once weelcly. This response was smliiar to that occurring after a 
twice-weekly treatment protocol with acetone; Pat/tis C and D: 48 and 96 h. respectively. after the last of five tre:aments with chrysarobm given once: 
weekly. The epidermis showed maximum hyperplasia and Des 48 It after the last treatment. At 96 h the epidermis Still showed a good hyperplasia. Pat/tis E 
and F: 48 and 96 h. respectivdy, after the last offive treatments with chrysarobin given twice weekly. At 48 h aftcrthe \:m treatment, the epidermisshowed a 
modcr:l.tc hyperplasia and altered morphology of epidermal cells. In addition, the number of the basal cells were reduced. At 96 h afu:r the last treatment, the 
epidt'rmis also showed a moder:ne hyperplasia. PtJllfU G and H: 48 and 96 h, respectively, after the i;u;t of five treatments With TPA given twice weekly. At 
both 48 and 96 h after the last treatment. the epidetmis showed good hyperplasia and a large number of Des. Epon-toluidme blue: x420. Bar: 50 11m. 
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Table IV. Effect of Application Frequency on Skin Tumor Promotion with Chrysarobin in SENCAR Mic~ 
---
Application 
Frequency 
per Week 
Time to Reach 
Promotcr Tumor Response Percent of Mice Papillomas 
(Dose) Plueau (Weeks) with Papillomas per Mouse" 
Once 
Twice 
Twice 
Chrysarobin (220 nmol) 
Chrysarobin (220 IImol) 
TPA (3.4 nmol) 
25 
30 
20 
93 10.7 ± 0.80 
92 5.4 ± 1.86 
100 21.7 ± 2.50 
• Thirty fem;tlc SEN CAR mIce wen used for e;tch eXpc'nmcnl:ll1 group. Amtn;tls were lIutiared wuh 25 nmol DMBA followed 2 weeki later by applicarionJ of chrysarobin (220 
nmol) or TPA (3.4 nmol). 
" Aver.llge number of p:lpillomu pc'r mouse:lt the time of the: rumor response platelu. All value'S ill die Table uc 51gmficantiy different from o ne anorher (p < .05). 
layed time course for the induction of epidermal hyperplasia after a 
single treatment which is very similar to the time course of hyper-
plasia induced by wounding or abrasion (33); 2) a significant reduc-
tion in the number of nucleated basal cells per unit length of base-
ment membrane with both a single treatment and twice-weekly 
applications; 3) the presence of basal cells with alrered morphology 
compared to the acetone-treated control (Fig 2, parlels A and C, and 
Fig 3, pant/s A and E); 4) the presence of cytoplasmic and nuclear 
swelling in the basal cells; and 5) the presence of a dermal inflamma-
tory response characterized by PMN infiltration and a thickened 
dermis . Recell[ work in our laboratory has demonstrated that in 
DBA/2 and CS7BL/6 mice, once-weekly treatmc:nts with chrysar-
obin also produced similar changes. In this regard. chrysarobin-
treated skins had fewer nucleated cells per unit length of DM and 
those cells again had altered morphology [27J. The absence of a 
reduced number of nucleated basal ce lls and abnormal cellmorphol-
ogy associated with a once-weekly application protocol in our 
present study (Fig 3, panels C and D) may be related to the use of a 
different mouse stock (i.e., SENCA R) compared to our previous 
studies. but does not preclude the presence of a toxic response. 
Rather, toxicity could be operative and present at a lower level. 
Further work will be necessary to fully substantiate the role of 
epidermal toxicity ill skin tumor promotion by anthrones. It is inter-
esting that in our present study the treatment protocol producing 
the least amOunt of observable toxic manifestations in skin sections 
was more effective at promoting skin papillomas. This finding is 
alsoconsiscent with the observationsofKlein-Szamo et al [34J, who 
showed that optimal promoting doses of TPA (i.e., 3.4 nmol) in 
SENCAR mice produce only moderate, sublethaJ damage to epider-
mal keratinocytes. 
DC induction, as analyzed by light microscopy. has been used as a 
morphologic indicator of an early stage of tumor promotion (Le., 
Stage I of promotion) POI. Using electron microscopy. Raick 
[35.36] first reported that the number of DCs in TPA-induced 
hyperplasia was greater than that in epidermal hyperplasia induced 
by skin wounding or the weak tumor promoter, EPt>. Chiba et al 
[37] classified TPA-induced DCs into Type-I and Type-H. Type-I 
DCs are poorly difterentiarcd or dc-diffetentiated cell s and consti-
tute the majority ofTPA-induccd DCs, while Type-II are involu-
tional or degenerative cells. In the present study we did not strictly 
classify DCs imo Type-I and Type-II. Several recent reports [27,381 
have suggested that DCs arc proliferating rather than degenerating 
cells as reported by others [39J. Although the function ofDCs is not 
understood as yet, it has been suggested that DCs may be epiderma l 
srem cells [401 . We observed that TPA induced more DCs than 
chrysarobin. but this difference was only statistically significam 
when comparing the multiple treatment promeols. There was also a 
potentiated induction of DCs following multiple treatments with 
the phorbol ester. This was also true for chrysarobin but only for the 
once-weekly application protocol. It is interesting to note that chry-
sarobin lacks Stage 1 promoting activity in SEN CAR mice [7J. Qur 
currenr histologic data suggest that the induction of DCs may be a 
nCCCSS:lry bur nOt sufficient condition for effecting Stage I of pro-
motion in SEN CAR mice. Nevertheless, our current data show a 
direct correlation between the papil loma promoting ability and DC 
inducin g ahility ofhoth chrysarobin and TPA. 
In summary. the data from the single and muldple treatmcm 
protocols demonstrate that chrysarobin and TPA are effective in-
ducers of hyperplasia. total number of nucleated epidermal ce ll s. 
DCs, and a dermal inflammatOry response. Our results with multi-
ple treatment protocols show a direct correlation between the 
greater ability of TPA to promote papillomas when compared [0 
chrysarobin using a two-stage carcinogenesis protocol in mouse 
skin (Refs 6 and 7 and Table IV). Also, results from multiple treat-
ment protocols with chrysarobin indicate that the greater ability of 
the once-weekly protocol (0 induce hyperplasia and [Otal epidcnnal 
cellularity correlates well with greater tumor promoting activity 
(Refs 8 and 25 and Table IV). These data clearly demonstrate thatan 
analysis of promoter-induced histologic alterations in mouse skin 
following multiple but nOt single trc:annent protocols is more pre-
dictive of promoter activ ity in terms of the papilloma response as 
suggested by others[3 I ,32]. Finally, a number of observations sug-
gest that anthrone-induced toxicity may be important in the pro-
duction of epidermal hyperplasia and tumor promotion in mouse 
skin. Further investigations arc currendy underway to understand 
the nature and importance of toxicity in the mechanism of tumor 
promotion by the amhrones. 
WI' lhank Ms. j. Mayhlj,~" and Ms. Judy lngfor t>:ptrt ossiSIOtlct in prtporirlg 'his 
,"orluscrjpl. 
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